An Open-Label Study to Estimate the Effect of Multiple Doses of Erythromycin on the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With Renal Impairment and Normal Renal Function.

Trial Profile

An Open-Label Study to Estimate the Effect of Multiple Doses of Erythromycin on the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With Renal Impairment and Normal Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2014

At a glance

  • Drugs Rivaroxaban (Primary) ; Erythromycin
  • Indications Acute coronary syndromes; Bacterial infections; Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 19 Apr 2012 Actual patient number (29) added as reported by ClinicalTrials.gov.
    • 19 Apr 2012 Actual end date (March 2012) added as reported by ClinicalTrials.gov.
    • 19 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top